Compare GIB & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIB | WAT |
|---|---|---|
| Founded | 1976 | 1958 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 23.0B |
| IPO Year | N/A | 1995 |
| Metric | GIB | WAT |
|---|---|---|
| Price | $90.59 | $383.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 15 |
| Target Price | $117.00 | ★ $388.67 |
| AVG Volume (30 Days) | 314.8K | ★ 527.7K |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | 0.55 | ★ 3.82 |
| EPS | 5.28 | ★ 10.88 |
| Revenue | ★ $11,424,213,683.00 | $3,105,638,000.00 |
| Revenue This Year | $8.52 | $7.96 |
| Revenue Next Year | $3.31 | $6.32 |
| P/E Ratio | ★ $17.18 | $35.43 |
| Revenue Growth | ★ 8.43 | 6.90 |
| 52 Week Low | $84.00 | $275.05 |
| 52 Week High | $122.79 | $423.56 |
| Indicator | GIB | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 50.66 |
| Support Level | $89.13 | $385.08 |
| Resistance Level | $92.32 | $397.55 |
| Average True Range (ATR) | 1.52 | 9.42 |
| MACD | 0.21 | -3.19 |
| Stochastic Oscillator | 57.85 | 7.46 |
CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.